- Cancer Type
- Biopsy Type
- Results Expected
What is FoundationOneHeme?
FoundationOneHeme is a comprehensive genomic profiling assay for hematologic malignancies and sarcomas. The test is designed to provide physicians with clinically actionable information to help with diagnostic subclassification, prognosis assessment, and targeted therapeutic selection. Test results provide information about clinically significant alterations, potential targeted therapies, available clinical trials, and quantitative markers that may support immunotherapy clinical trial enrollment.
FoundationOneHeme is validated to detect all classes of genomic alterations in more than 400 cancer-related genes. In addition to DNA sequencing, FoundationOneHeme employs RNA sequencing across more than 250 genes to capture a broad range of gene fusions, common drivers of hematologic malignancies, and sarcomas.
select introns profiled
- A single assay that detects all four classes of genomic alterations for hematologic cancers and sarcomas
- Uses both DNA and RNA sequencing for sensitive detection of translocations and fusions
- Reports high tumor mutational burden (TMB), which may support therapy selection and clinical trial enrollment